                                                                                                                                                                               20749

                                               Federal Register                                   Presidential Documents
                                               Vol. 90, No. 93

                                               Thursday, May 15, 2025



                                               Title 3—                                           Executive Order 14297 of May 12, 2025

                                               The President                                      Delivering Most-Favored-Nation Prescription Drug Pricing to
                                                                                                  American Patients


                                                                                                  By the authority vested in me as President by the Constitution and the
                                                                                                  laws of the United States of America, it is hereby ordered:
                                                                                                  Section 1. Purpose. The United States has less than five percent of the
                                                                                                  world’s population and yet funds around three quarters of global pharma-
                                                                                                  ceutical profits. This egregious imbalance is orchestrated through a purpose-
                                                                                                  ful scheme in which drug manufacturers deeply discount their products
                                                                                                  to access foreign markets, and subsidize that decrease through enormously
                                                                                                  high prices in the United States.
                                                                                                  The United States has for too long turned its back on Americans, who
                                                                                                  unwittingly sponsor both drug manufacturers and other countries. These
                                                                                                  entities today rely on price markups on American consumers, generous
                                                                                                  public subsidies for research and development primarily through the National
                                                                                                  Institutes of Health, and robust public financing of prescription drug con-
                                                                                                  sumption through Federal and State healthcare programs. Drug manufactur-
                                                                                                  ers, rather than seeking to equalize evident price discrimination, agree to
                                                                                                  other countries’ demands for low prices, and simultaneously fight against
                                                                                                  the ability for public and private payers in the United States to negotiate
                                                                                                  the best prices for patients. The inflated prices in the United States fuel
                                                                                                  global innovation while foreign health systems get a free ride.
                                                                                                  This abuse of Americans’ generosity, who deserve low-cost pharmaceuticals
                                                                                                  on the same terms as other developed nations, must end. Americans will
                                                                                                  no longer be forced to pay almost three times more for the exact same
                                                                                                  medicines, often made in the exact same factories. As the largest purchaser
                                                                                                  of pharmaceuticals, Americans should get the best deal.
                                                                                                  Sec. 2. Policy. Americans should not be forced to subsidize low-cost prescrip-
                                                                                                  tion drugs and biologics in other developed countries, and face overcharges
                                                                                                  for the same products in the United States. Americans must therefore have
                                                                                                  access to the most-favored-nation price for these products.
                                                                                                  My Administration will take immediate steps to end global freeloading and,
                                                                                                  should drug manufacturers fail to offer American consumers the most-fa-
                                                                                                  vored-nation lowest price, my Administration will take additional aggressive
                                                                                                  action.
                                                                                                  Sec. 3. Addressing Foreign Nations Freeloading on American-Financed Inno-
                                                                                                  vation. The Secretary of Commerce and the United States Trade Representa-
                                                                                                  tive shall take all necessary and appropriate action to ensure foreign countries
                                                                                                  are not engaged in any act, policy, or practice that may be unreasonable
                                                                                                  or discriminatory or that may impair United States national security and
                                                                                                  that has the effect of forcing American patients to pay for a disproportionate
                                                                                                  amount of global pharmaceutical research and development, including by
khammond on DSK9W7S144PROD with PRESDOC




                                                                                                  suppressing the price of pharmaceutical products below fair market value
                                                                                                  in foreign countries.
                                                                                                  Sec. 4. Enabling Direct-to-Consumer Sales to American Patients at the Most-
                                                                                                  Favored-Nation Price. To the extent consistent with law, the Secretary of
                                                                                                  Health and Human Services (Secretary) shall facilitate direct-to-consumer
                                                                                                  purchasing programs for pharmaceutical manufacturers that sell their prod-
                                                                                                  ucts to American patients at the most-favored-nation price.


                                          VerDate Sep<11>2014   16:49 May 14, 2025   Jkt 265001   PO 00000   Frm 00003   Fmt 4705   Sfmt 4790   E:\FR\FM\15MYE0.SGM   15MYE0


                                               20750                Federal Register / Vol. 90, No. 93 / Thursday, May 15, 2025 / Presidential Documents

                                                                                                  Sec. 5. Establishing Most-Favored-Nation Pricing. (a) Within 30 days of
                                                                                                  the date of this order, the Secretary shall, in coordination with the Assistant
                                                                                                  to the President for Domestic Policy, the Administrator for the Centers
                                                                                                  for Medicare and Medicaid Services, and other relevant executive department
                                                                                                  and agency (agency) officials, communicate most-favored-nation price targets
                                                                                                  to pharmaceutical manufacturers to bring prices for American patients in
                                                                                                  line with comparably developed nations.
                                                                                                     (b) If, following the action described in subsection (a) of this section,
                                                                                                  significant progress towards most-favored-nation pricing for American pa-
                                                                                                  tients is not delivered, to the extent consistent with law:
                                                                                                     (i) the Secretary shall propose a rulemaking plan to impose most-favored-
                                                                                                     nation pricing;
                                                                                                     (ii) the Secretary shall consider certification to the Congress that importa-
                                                                                                     tion under section 804(j) of the Federal Food, Drug, and Cosmetic Act
                                                                                                     (FDCA) will pose no additional risk to the public’s health and safety
                                                                                                     and result in a significant reduction in the cost of prescription drugs
                                                                                                     to the American consumer; and if the Secretary so certifies, then the
                                                                                                     Commissioner of Food and Drugs shall take action under section
                                                                                                     804(j)(2)(B) of the FDCA to describe circumstances under which waivers
                                                                                                     will be consistently granted to import prescription drugs on a case-by-
                                                                                                     case basis from developed nations with low-cost prescription drugs;
                                                                                                     (iii) following the report issued under section 13 of Executive Order 14273
                                                                                                     of April 15, 2025 (Lowering Drug Prices by Once Again Putting Americans
                                                                                                     First), the Attorney General and the Chairman of the Federal Trade Com-
                                                                                                     mission shall, to the extent consistent with law, undertake enforcement
                                                                                                     action against any anti-competitive practices identified within such report,
                                                                                                     including through use of sections 1 and 2 of the Sherman Antitrust Act
                                                                                                     and section 5 of the Federal Trade Commission Act, as appropriate;
                                                                                                     (iv) the Secretary of Commerce, and the heads of other relevant agencies
                                                                                                     as necessary, shall review and consider all necessary action regarding
                                                                                                     the export of pharmaceutical drugs or precursor material that may be
                                                                                                     fueling the global price discrimination;
                                                                                                     (v) the Commissioner of Food and Drugs shall review and potentially
                                                                                                     modify or revoke approvals granted for drugs, for those drugs that maybe
                                                                                                     be unsafe, ineffective, or improperly marketed; and
                                                                                                    (vi) the heads of agencies shall take all action available, in coordination
                                                                                                    with the Assistant to the President for Domestic Policy, to address global
                                                                                                    freeloading and price discrimination against American patients.
                                                                                                  Sec. 6. General Provisions. (a) Nothing in this order shall be construed
                                                                                                  to impair or otherwise affect:
                                                                                                    (i) the authority granted by law to an executive department or agency,
                                                                                                    or the head thereof; or
                                                                                                    (ii) the functions of the Director of the Office of Management and Budget
                                                                                                    relating to budgetary, administrative, or legislative proposals.
                                                                                                    (b) This order shall be implemented consistent with applicable law and
                                                                                                  subject to the availability of appropriations.
                                                                                                    (c) This order is not intended to, and does not, create any right or benefit,
                                                                                                  substantive or procedural, enforceable at law or in equity by any party
                                                                                                  against the United States, its departments, agencies, or entities, its officers,
                                                                                                  employees, or agents, or any other person.
khammond on DSK9W7S144PROD with PRESDOC




                                          VerDate Sep<11>2014   16:49 May 14, 2025   Jkt 265001   PO 00000   Frm 00004   Fmt 4705   Sfmt 4790   E:\FR\FM\15MYE0.SGM   15MYE0


                                                                    Federal Register / Vol. 90, No. 93 / Thursday, May 15, 2025 / Presidential Documents                       20751

                                                                                                    (d) The Department of Health and Human Services shall provide funding
                                                                                                  for publication of this order in the Federal Register.




                                                                                                  THE WHITE HOUSE,
                                                                                                  May 12, 2025.


                                               [FR Doc. 2025–08876
                                               Filed 5–14–25; 2:00 pm]
                                               Billing code 4150–28–P
khammond on DSK9W7S144PROD with PRESDOC




                                                                                                                                                                                       Trump.EPS</GPH>




                                          VerDate Sep<11>2014   16:49 May 14, 2025   Jkt 265001   PO 00000   Frm 00005   Fmt 4705   Sfmt 4790   E:\FR\FM\15MYE0.SGM   15MYE0
